Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor plus aspirin versus aspirin alone in acute ischemic stroke or transient ischemic attack
2016-004232-37Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ticagrelor, aspirin in ischemic stroke, transient ischaemic attack (TIA), sponsored by AstraZeneca. Started Oct 2017; status: completed.
02
Drugs
ticagreloraspirin
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2016-004232-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004232-37.